Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study
Identifieur interne : 002290 ( Istex/Corpus ); précédent : 002289; suivant : 002291Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study
Auteurs : Albert F. G. Leentjens ; Kathy Dujardin ; Laura Marsh ; Pablo Martinez-Martin ; Irene H. Richard ; Sergio E. StarksteinSource :
- Movement Disorders [ 0885-3185 ] ; 2011-02-15.
English descriptors
- KwdEn :
- Acute stress syndrome, Agoraphobia, Anxiety, Anxiety disorder, Anxiety disorders, Anxiety rating scales, Anxiety symptoms, Anxiety syndromes, Anxiety tension fear sleeplessness depression, Autonomic dysfunction, Beck, Beck anxiety inventory, Breathing fear, Clinical interview, Continuous variables, Depressive, Depressive symptoms, Diagnostic categories, Diagnostic groups, Different anxiety disorders, Disease duration, Disease rating scale, Disord, Disorder, Generalized anxiety disorder, Hamilton anxiety rating scale, Hamilton depression rating scale, Hars, Hars item scores, Hoehn yahr stage, Iadl, Independent variables, Indigestion face, Individual anxiety disorders, Individual anxiety syndromes, Individual item level, Individual items, Inhibitor, Instrumental activities, Item scores, Lemeshow test, Lightheaded heart, Limited number, Logistic, Logistic model, Logistic regression, Logistic regression analysis, Maastricht university, Major depressive episode, Meeting criteria, Mini, Mini interview, Movement disorder society, Movement disorders, Multiple anxiety disorders, Multiple anxiety syndromes, Neurol neurosurg psychiatr, Neuropsychiatry clin neurosci, Odds ratios, Other anxiety disorders, Panic disorder, Phobia, Pontone, Potential markers, Prevalence, Prevalence rates, Prevalent disorders, Previous history, Primary care, Psychometric properties, Questionable validity, Relevant anxiety, Relevant anxiety symptoms, Risk factors, Same analysis, Social phobia, Social phobia agoraphobia, Standard deviation, State examination, Stress syndrome, Study reports, Symptom, Symptoms senses, Syndrome, Test statistic, Uctuations, Updrs, Updrs item, Validation study, Various anxiety disorders, Wilks lambda, Work group.
- Teeft :
- Acute stress syndrome, Agoraphobia, Anxiety, Anxiety disorder, Anxiety disorders, Anxiety rating scales, Anxiety symptoms, Anxiety syndromes, Anxiety tension fear sleeplessness depression, Autonomic dysfunction, Beck, Beck anxiety inventory, Breathing fear, Clinical interview, Continuous variables, Depressive, Depressive symptoms, Diagnostic categories, Diagnostic groups, Different anxiety disorders, Disease duration, Disease rating scale, Disord, Disorder, Generalized anxiety disorder, Hamilton anxiety rating scale, Hamilton depression rating scale, Hars, Hars item scores, Hoehn yahr stage, Iadl, Independent variables, Indigestion face, Individual anxiety disorders, Individual anxiety syndromes, Individual item level, Individual items, Inhibitor, Instrumental activities, Item scores, Lemeshow test, Lightheaded heart, Limited number, Logistic, Logistic model, Logistic regression, Logistic regression analysis, Maastricht university, Major depressive episode, Meeting criteria, Mini, Mini interview, Movement disorder society, Movement disorders, Multiple anxiety disorders, Multiple anxiety syndromes, Neurol neurosurg psychiatr, Neuropsychiatry clin neurosci, Odds ratios, Other anxiety disorders, Panic disorder, Phobia, Pontone, Potential markers, Prevalence, Prevalence rates, Prevalent disorders, Previous history, Primary care, Psychometric properties, Questionable validity, Relevant anxiety, Relevant anxiety symptoms, Risk factors, Same analysis, Social phobia, Social phobia agoraphobia, Standard deviation, State examination, Stress syndrome, Study reports, Symptom, Symptoms senses, Syndrome, Test statistic, Uctuations, Updrs, Updrs item, Validation study, Various anxiety disorders, Wilks lambda, Work group.
Abstract
Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross‐sectional study, 342 patients suffering from idiopathic PD underwent a research‐based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty‐four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono‐amino oxidase (MAO)‐B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23528
Links to Exploration step
ISTEX:BAC9A14C486FC4DDDE842C685558E2300E5FB8FBLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study</title><author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name><affiliation><mods:affiliation>Department of Psychiatry, Maastricht University Medical Center, Maastricht, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: a.leentjens@np.unimaas.nl</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Department of Psychiatry, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation><mods:affiliation>Neurology and Movement Disorders Unit, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation><mods:affiliation>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Mental Health Care Line, Michael E. DeBakey Veterans Administration Medical Center and Menninger Department of Psychiatry, Baylor College of Medicine, Houston, USA</mods:affiliation></affiliation></author><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name><affiliation><mods:affiliation>Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, USA</mods:affiliation></affiliation></author><author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name><affiliation><mods:affiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Australia</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BAC9A14C486FC4DDDE842C685558E2300E5FB8FB</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23528</idno><idno type="url">https://api.istex.fr/document/BAC9A14C486FC4DDDE842C685558E2300E5FB8FB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002290</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002290</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study<ref type="note" target="#fn"></ref></title><author><name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name><affiliation><mods:affiliation>Department of Psychiatry, Maastricht University Medical Center, Maastricht, The Netherlands</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: a.leentjens@np.unimaas.nl</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Department of Psychiatry, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name><affiliation><mods:affiliation>Neurology and Movement Disorders Unit, Lille University Hospital, Lille, France</mods:affiliation></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation><mods:affiliation>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Mental Health Care Line, Michael E. DeBakey Veterans Administration Medical Center and Menninger Department of Psychiatry, Baylor College of Medicine, Houston, USA</mods:affiliation></affiliation></author><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name><affiliation><mods:affiliation>Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, USA</mods:affiliation></affiliation></author><author><name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name><affiliation><mods:affiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Australia</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Movement Disorders</title><title level="j" type="alt">MOVEMENT DISORDERS</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><biblScope unit="vol">26</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="484">484</biblScope><biblScope unit="page" to="492">492</biblScope><biblScope unit="page-count">9</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-02-15">2011-02-15</date></imprint><idno type="ISSN">0885-3185</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute stress syndrome</term><term>Agoraphobia</term><term>Anxiety</term><term>Anxiety disorder</term><term>Anxiety disorders</term><term>Anxiety rating scales</term><term>Anxiety symptoms</term><term>Anxiety syndromes</term><term>Anxiety tension fear sleeplessness depression</term><term>Autonomic dysfunction</term><term>Beck</term><term>Beck anxiety inventory</term><term>Breathing fear</term><term>Clinical interview</term><term>Continuous variables</term><term>Depressive</term><term>Depressive symptoms</term><term>Diagnostic categories</term><term>Diagnostic groups</term><term>Different anxiety disorders</term><term>Disease duration</term><term>Disease rating scale</term><term>Disord</term><term>Disorder</term><term>Generalized anxiety disorder</term><term>Hamilton anxiety rating scale</term><term>Hamilton depression rating scale</term><term>Hars</term><term>Hars item scores</term><term>Hoehn yahr stage</term><term>Iadl</term><term>Independent variables</term><term>Indigestion face</term><term>Individual anxiety disorders</term><term>Individual anxiety syndromes</term><term>Individual item level</term><term>Individual items</term><term>Inhibitor</term><term>Instrumental activities</term><term>Item scores</term><term>Lemeshow test</term><term>Lightheaded heart</term><term>Limited number</term><term>Logistic</term><term>Logistic model</term><term>Logistic regression</term><term>Logistic regression analysis</term><term>Maastricht university</term><term>Major depressive episode</term><term>Meeting criteria</term><term>Mini</term><term>Mini interview</term><term>Movement disorder society</term><term>Movement disorders</term><term>Multiple anxiety disorders</term><term>Multiple anxiety syndromes</term><term>Neurol neurosurg psychiatr</term><term>Neuropsychiatry clin neurosci</term><term>Odds ratios</term><term>Other anxiety disorders</term><term>Panic disorder</term><term>Phobia</term><term>Pontone</term><term>Potential markers</term><term>Prevalence</term><term>Prevalence rates</term><term>Prevalent disorders</term><term>Previous history</term><term>Primary care</term><term>Psychometric properties</term><term>Questionable validity</term><term>Relevant anxiety</term><term>Relevant anxiety symptoms</term><term>Risk factors</term><term>Same analysis</term><term>Social phobia</term><term>Social phobia agoraphobia</term><term>Standard deviation</term><term>State examination</term><term>Stress syndrome</term><term>Study reports</term><term>Symptom</term><term>Symptoms senses</term><term>Syndrome</term><term>Test statistic</term><term>Uctuations</term><term>Updrs</term><term>Updrs item</term><term>Validation study</term><term>Various anxiety disorders</term><term>Wilks lambda</term><term>Work group</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Acute stress syndrome</term><term>Agoraphobia</term><term>Anxiety</term><term>Anxiety disorder</term><term>Anxiety disorders</term><term>Anxiety rating scales</term><term>Anxiety symptoms</term><term>Anxiety syndromes</term><term>Anxiety tension fear sleeplessness depression</term><term>Autonomic dysfunction</term><term>Beck</term><term>Beck anxiety inventory</term><term>Breathing fear</term><term>Clinical interview</term><term>Continuous variables</term><term>Depressive</term><term>Depressive symptoms</term><term>Diagnostic categories</term><term>Diagnostic groups</term><term>Different anxiety disorders</term><term>Disease duration</term><term>Disease rating scale</term><term>Disord</term><term>Disorder</term><term>Generalized anxiety disorder</term><term>Hamilton anxiety rating scale</term><term>Hamilton depression rating scale</term><term>Hars</term><term>Hars item scores</term><term>Hoehn yahr stage</term><term>Iadl</term><term>Independent variables</term><term>Indigestion face</term><term>Individual anxiety disorders</term><term>Individual anxiety syndromes</term><term>Individual item level</term><term>Individual items</term><term>Inhibitor</term><term>Instrumental activities</term><term>Item scores</term><term>Lemeshow test</term><term>Lightheaded heart</term><term>Limited number</term><term>Logistic</term><term>Logistic model</term><term>Logistic regression</term><term>Logistic regression analysis</term><term>Maastricht university</term><term>Major depressive episode</term><term>Meeting criteria</term><term>Mini</term><term>Mini interview</term><term>Movement disorder society</term><term>Movement disorders</term><term>Multiple anxiety disorders</term><term>Multiple anxiety syndromes</term><term>Neurol neurosurg psychiatr</term><term>Neuropsychiatry clin neurosci</term><term>Odds ratios</term><term>Other anxiety disorders</term><term>Panic disorder</term><term>Phobia</term><term>Pontone</term><term>Potential markers</term><term>Prevalence</term><term>Prevalence rates</term><term>Prevalent disorders</term><term>Previous history</term><term>Primary care</term><term>Psychometric properties</term><term>Questionable validity</term><term>Relevant anxiety</term><term>Relevant anxiety symptoms</term><term>Risk factors</term><term>Same analysis</term><term>Social phobia</term><term>Social phobia agoraphobia</term><term>Standard deviation</term><term>State examination</term><term>Stress syndrome</term><term>Study reports</term><term>Symptom</term><term>Symptoms senses</term><term>Syndrome</term><term>Test statistic</term><term>Uctuations</term><term>Updrs</term><term>Updrs item</term><term>Validation study</term><term>Various anxiety disorders</term><term>Wilks lambda</term><term>Work group</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross‐sectional study, 342 patients suffering from idiopathic PD underwent a research‐based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty‐four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono‐amino oxidase (MAO)‐B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>anxiety disorders</json:string><json:string>anxiety disorder</json:string><json:string>phobia</json:string><json:string>agoraphobia</json:string><json:string>hars</json:string><json:string>panic disorder</json:string><json:string>mini</json:string><json:string>social phobia</json:string><json:string>disorder</json:string><json:string>depressive</json:string><json:string>uctuations</json:string><json:string>pontone</json:string><json:string>disord</json:string><json:string>iadl</json:string><json:string>updrs</json:string><json:string>movement disorders</json:string><json:string>anxiety syndromes</json:string><json:string>hamilton anxiety rating scale</json:string><json:string>anxiety rating scales</json:string><json:string>previous history</json:string><json:string>logistic model</json:string><json:string>generalized anxiety disorder</json:string><json:string>beck anxiety inventory</json:string><json:string>social phobia agoraphobia</json:string><json:string>different anxiety disorders</json:string><json:string>syndrome</json:string><json:string>independent variables</json:string><json:string>multiple anxiety disorders</json:string><json:string>anxiety symptoms</json:string><json:string>diagnostic categories</json:string><json:string>depressive symptoms</json:string><json:string>various anxiety disorders</json:string><json:string>mini interview</json:string><json:string>disease duration</json:string><json:string>risk factors</json:string><json:string>wilks lambda</json:string><json:string>logistic regression analysis</json:string><json:string>beck</json:string><json:string>hamilton depression rating scale</json:string><json:string>lemeshow test</json:string><json:string>primary care</json:string><json:string>instrumental activities</json:string><json:string>individual anxiety syndromes</json:string><json:string>disease rating scale</json:string><json:string>neurol neurosurg psychiatr</json:string><json:string>major depressive episode</json:string><json:string>inhibitor</json:string><json:string>logistic</json:string><json:string>symptom</json:string><json:string>anxiety</json:string><json:string>prevalence</json:string><json:string>other anxiety disorders</json:string><json:string>standard deviation</json:string><json:string>continuous variables</json:string><json:string>state examination</json:string><json:string>multiple anxiety syndromes</json:string><json:string>hoehn yahr stage</json:string><json:string>odds ratios</json:string><json:string>logistic regression</json:string><json:string>potential markers</json:string><json:string>individual anxiety disorders</json:string><json:string>relevant anxiety</json:string><json:string>hars item scores</json:string><json:string>meeting criteria</json:string><json:string>test statistic</json:string><json:string>anxiety tension fear sleeplessness depression</json:string><json:string>symptoms senses</json:string><json:string>item scores</json:string><json:string>lightheaded heart</json:string><json:string>breathing fear</json:string><json:string>indigestion face</json:string><json:string>stress syndrome</json:string><json:string>diagnostic groups</json:string><json:string>same analysis</json:string><json:string>study reports</json:string><json:string>movement disorder society</json:string><json:string>questionable validity</json:string><json:string>individual items</json:string><json:string>individual item level</json:string><json:string>updrs item</json:string><json:string>prevalence rates</json:string><json:string>prevalent disorders</json:string><json:string>limited number</json:string><json:string>clinical interview</json:string><json:string>relevant anxiety symptoms</json:string><json:string>autonomic dysfunction</json:string><json:string>validation study</json:string><json:string>acute stress syndrome</json:string><json:string>neuropsychiatry clin neurosci</json:string><json:string>psychometric properties</json:string><json:string>maastricht university</json:string><json:string>work group</json:string></teeft></keywords><author><json:item><name>Albert F. G. Leentjens MD, PhD</name><affiliations><json:string>Department of Psychiatry, Maastricht University Medical Center, Maastricht, The Netherlands</json:string><json:string>E-mail: a.leentjens@np.unimaas.nl</json:string><json:string>Correspondence address: Department of Psychiatry, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands</json:string></affiliations></json:item><json:item><name>Kathy Dujardin PhD</name><affiliations><json:string>Neurology and Movement Disorders Unit, Lille University Hospital, Lille, France</json:string></affiliations></json:item><json:item><name>Laura Marsh MD</name><affiliations><json:string>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, USA</json:string><json:string>Current Address: Mental Health Care Line, Michael E. DeBakey Veterans Administration Medical Center and Menninger Department of Psychiatry, Baylor College of Medicine, Houston, USA</json:string></affiliations></json:item><json:item><name>Pablo Martinez‐Martin MD, PhD</name><affiliations><json:string>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Irene H. Richard MD</name><affiliations><json:string>Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, USA</json:string></affiliations></json:item><json:item><name>Sergio E. Starkstein MD</name><affiliations><json:string>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Australia</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>anxiety</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>depression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Hamilton Anxiety Rating Scale (HARS)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Beck Anxiety Inventory (BAI)</value></json:item></subject><articleId><json:string>MDS23528</json:string></articleId><arkIstex>ark:/67375/WNG-DGPX2V39-0</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross‐sectional study, 342 patients suffering from idiopathic PD underwent a research‐based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty‐four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono‐amino oxidase (MAO)‐B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>9.604</score><pdfWordCount>5455</pdfWordCount><pdfCharCount>37454</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>9</pdfPageCount><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>217</abstractWordCount><abstractCharCount>1446</abstractCharCount><keywordCount>5</keywordCount></qualityIndicators><title>Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study</title><pmid><json:string>21312281</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Movement Disorders</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi><issn><json:string>0885-3185</json:string></issn><eissn><json:string>1531-8257</json:string></eissn><publisherId><json:string>MDS</json:string></publisherId><volume>26</volume><issue>3</issue><pages><first>484</first><last>492</last><total>9</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Research Article</value></json:item></subject></host><namedEntities><unitex><date><json:string>2011</json:string></date><geogName></geogName><orgName><json:string>University of Rochester School of Medicine</json:string><json:string>Institute of Health, Madrid, Spain</json:string><json:string>United States, Europe, and Australia</json:string><json:string>Johns Hopkins University</json:string><json:string>NINDS/NIMH Work Group on Depression and Parkinson's Disease</json:string><json:string>Department of Psychiatry, Maastricht University Medical Center, Maastricht, The Netherlands</json:string><json:string>Lille University Hospital, Lille, France</json:string><json:string>members of the French Selegeline Multicenter trial</json:string><json:string>American Psychiatric Association</json:string><json:string>Mini International</json:string><json:string>National Centre for Epidemiology, Carlos</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Gi Urogenital</json:string><json:string>Laura Marsh</json:string><json:string>Pablo Martinez-Martin</json:string><json:string>Kathy Dujardin</json:string><json:string>Irene H. Richard</json:string><json:string>To</json:string><json:string>Sergio E. Starkstein</json:string></persName><placeName><json:string>Rochester</json:string><json:string>Chicago</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Sherbourne et al.</json:string><json:string>Pontone et al.</json:string><json:string>Dissanayaka et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-DGPX2V39-0</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - clinical neurology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - neurology & neurosurgery</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Clinical Neurology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Neuroscience</json:string><json:string>3 - Neurology</json:string></scopus><inist><json:string>1 - sciences humaines et sociales</json:string></inist></categories><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23528</json:string></doi><id>BAC9A14C486FC4DDDE842C685558E2300E5FB8FB</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/BAC9A14C486FC4DDDE842C685558E2300E5FB8FB/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/BAC9A14C486FC4DDDE842C685558E2300E5FB8FB/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/BAC9A14C486FC4DDDE842C685558E2300E5FB8FB/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study<ref type="note" target="#fn"></ref></title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><licence>Copyright © 2011 Movement Disorder Society</licence></availability><date type="published" when="2011-02-15"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study<ref type="note" target="#fn"></ref></title><title level="a" type="short" xml:lang="en">Symptomatology and Markers of Anxiety Disorders in PD</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Albert F. G.</forename><surname>Leentjens</surname><roleName type="degree">MD, PhD</roleName></persName><email>a.leentjens@np.unimaas.nl</email><affiliation>Department of Psychiatry, Maastricht University Medical Center, Maastricht, The Netherlands<address><country key="NL"></country></address></affiliation><affiliation>Department of Psychiatry, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Kathy</forename><surname>Dujardin</surname><roleName type="degree">PhD</roleName></persName><affiliation>Neurology and Movement Disorders Unit, Lille University Hospital, Lille, France<address><country key="FR"></country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Laura</forename><surname>Marsh</surname><roleName type="degree">MD</roleName></persName><affiliation>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, USA<address><country key="US"></country></address></affiliation><affiliation>Current Address: Mental Health Care Line, Michael E. DeBakey Veterans Administration Medical Center and Menninger Department of Psychiatry, Baylor College of Medicine, Houston, USA</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Pablo</forename><surname>Martinez‐Martin</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain<address><country key="ES"></country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Irene H.</forename><surname>Richard</surname><roleName type="degree">MD</roleName></persName><affiliation>Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, USA<address><country key="US"></country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Sergio E.</forename><surname>Starkstein</surname><roleName type="degree">MD</roleName></persName><affiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Australia<address><country key="AU"></country></address></affiliation></author><idno type="istex">BAC9A14C486FC4DDDE842C685558E2300E5FB8FB</idno><idno type="ark">ark:/67375/WNG-DGPX2V39-0</idno><idno type="DOI">10.1002/mds.23528</idno><idno type="unit">MDS23528</idno><idno type="toTypesetVersion">file:MDS.MDS23528.pdf</idno></analytic><monogr><title level="j" type="main">Movement Disorders</title><title level="j" type="alt">MOVEMENT DISORDERS</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="book-DOI">10.1002/(ISSN)1531-8257</idno><idno type="book-part-DOI">10.1002/mds.v26.3</idno><idno type="product">MDS</idno><imprint><biblScope unit="vol">26</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="484">484</biblScope><biblScope unit="page" to="492">492</biblScope><biblScope unit="page-count">9</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-02-15"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross‐sectional study, 342 patients suffering from idiopathic PD underwent a research‐based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI).</p><p>Thirty‐four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono‐amino oxidase (MAO)‐B inhibitor was associated with a reduced prevalence of anxiety disorders.</p><p>Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD. © 2011 Movement Disorder Society</p></abstract><textClass><keywords xml:lang="en"><term xml:id="kwd1">anxiety</term><term xml:id="kwd2">depression</term><term xml:id="kwd3">Parkinson's disease</term><term xml:id="kwd4">Hamilton Anxiety Rating Scale (HARS)</term><term xml:id="kwd5">Beck Anxiety Inventory (BAI)</term></keywords><keywords rend="articleCategory"><term>Research Article</term></keywords><keywords rend="tocHeading1"><term>Research Articles</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/BAC9A14C486FC4DDDE842C685558E2300E5FB8FB/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/mds.v26.3</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2011-02-15">15 February 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="210" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23528</doi><idGroup><id type="unit" value="MDS23528"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-06-09"></event><event type="manuscriptRevised" date="2010-09-03"></event><event type="manuscriptAccepted" date="2010-10-19"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2012-01-12"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-02-10"></event><event type="publishedOnlineFinalForm" date="2011-03-31"></event><event type="firstOnline" date="2011-02-10"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">484</numbering><numbering type="pageLast">492</numbering></numberingGroup><correspondenceTo>Department of Psychiatry, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23528.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="9"></count><count type="referenceTotal" number="29"></count><count type="wordTotal" number="11085"></count></countGroup><titleGroup><title type="main" xml:lang="en">Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study<link href="#fn"></link></title><title type="short" xml:lang="en">Symptomatology and Markers of Anxiety Disorders in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Albert F. G.</givenNames><familyName>Leentjens</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>a.leentjens@np.unimaas.nl</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Kathy</givenNames><familyName>Dujardin</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3" currentRef="#curr1"><personName><givenNames>Laura</givenNames><familyName>Marsh</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Pablo</givenNames><familyName>Martinez‐Martin</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Irene H.</givenNames><familyName>Richard</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Sergio E.</givenNames><familyName>Starkstein</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="NL" type="organization"><unparsedAffiliation>Department of Psychiatry, Maastricht University Medical Center, Maastricht, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Neurology and Movement Disorders Unit, Lille University Hospital, Lille, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="ES" type="organization"><unparsedAffiliation>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="AU" type="organization"><unparsedAffiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Australia</unparsedAffiliation></affiliation><affiliation xml:id="curr1"><unparsedAffiliation>Mental Health Care Line, Michael E. DeBakey Veterans Administration Medical Center and Menninger Department of Psychiatry, Baylor College of Medicine, Houston, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">anxiety</keyword><keyword xml:id="kwd2">depression</keyword><keyword xml:id="kwd3">Parkinson's disease</keyword><keyword xml:id="kwd4">Hamilton Anxiety Rating Scale (HARS)</keyword><keyword xml:id="kwd5">Beck Anxiety Inventory (BAI)</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross‐sectional study, 342 patients suffering from idiopathic PD underwent a research‐based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI).</p><p>Thirty‐four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono‐amino oxidase (MAO)‐B inhibitor was associated with a reduced prevalence of anxiety disorders.</p><p>Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD. © 2011 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn"><p><b>Relevant conflicts of interest/financial disclosures:</b> Nothing to report. This study was sponsored by a grant from the Michael J. Fox Foundation for Parkinson Research (MJFF; <url href="http://www.michaeljfox.org">www.michaeljfox.org</url>).</p><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Symptomatology and Markers of Anxiety Disorders in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study</title></titleInfo><name type="personal"><namePart type="given">Albert F. G.</namePart><namePart type="family">Leentjens</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Psychiatry, Maastricht University Medical Center, Maastricht, The Netherlands</affiliation><affiliation>E-mail: a.leentjens@np.unimaas.nl</affiliation><affiliation>Correspondence address: Department of Psychiatry, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kathy</namePart><namePart type="family">Dujardin</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Neurology and Movement Disorders Unit, Lille University Hospital, Lille, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laura</namePart><namePart type="family">Marsh</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore, USA</affiliation><affiliation>Current Address: Mental Health Care Line, Michael E. DeBakey Veterans Administration Medical Center and Menninger Department of Psychiatry, Baylor College of Medicine, Houston, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pablo</namePart><namePart type="family">Martinez‐Martin</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Irene H.</namePart><namePart type="family">Richard</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sergio E.</namePart><namePart type="family">Starkstein</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-02-15</dateIssued><dateCaptured encoding="w3cdtf">2010-06-09</dateCaptured><dateValid encoding="w3cdtf">2010-10-19</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">9</extent><extent unit="references">29</extent><extent unit="words">11085</extent></physicalDescription><abstract lang="en">Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross‐sectional study, 342 patients suffering from idiopathic PD underwent a research‐based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty‐four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono‐amino oxidase (MAO)‐B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD. © 2011 Movement Disorder Society</abstract><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report. This study was sponsored by a grant from the Michael J. Fox Foundation for Parkinson Research (MJFF; www.michaeljfox.org). Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>keywords</genre><topic>anxiety</topic><topic>depression</topic><topic>Parkinson's disease</topic><topic>Hamilton Anxiety Rating Scale (HARS)</topic><topic>Beck Anxiety Inventory (BAI)</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>484</start><end>492</end><total>9</total></extent></part></relatedItem><identifier type="istex">BAC9A14C486FC4DDDE842C685558E2300E5FB8FB</identifier><identifier type="ark">ark:/67375/WNG-DGPX2V39-0</identifier><identifier type="DOI">10.1002/mds.23528</identifier><identifier type="ArticleID">MDS23528</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/BAC9A14C486FC4DDDE842C685558E2300E5FB8FB/metadata/json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002290 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002290 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:BAC9A14C486FC4DDDE842C685558E2300E5FB8FB
|texte= Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study
}}
| This area was generated with Dilib version V0.6.33. |  |